Preop Nivolumab Plus Chemo ' a Quantum Leap ' in NSCLC Therapy Preop Nivolumab Plus Chemo ' a Quantum Leap ' in NSCLC Therapy

Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news